In vivo targeting of B-cell lymphoma with glycan ligands of CD22.
暂无分享,去创建一个
James C Paulson | A. Saven | J. Paulson | P. Crocker | W. Chen | D. Sigal | Paul R Crocker | Gladys C Completo | Darren S Sigal | Weihsu C Chen | Alan Saven | G. Completo
[1] J. Marth,et al. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[2] N. Damle,et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia , 2007, Leukemia.
[3] A. Gabizon,et al. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. , 2008, Clinical lymphoma & myeloma.
[4] R. Braziel,et al. Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. , 2005, American journal of clinical pathology.
[5] A. Avilés,et al. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma , 2002, Medical Oncology.
[6] W. Wakarchuk,et al. Distinct Endocytic Mechanisms of CD22 (Siglec-2) and Siglec-F Reflect Roles in Cell Signaling and Innate Immunity , 2007, Molecular and Cellular Biology.
[7] H. Shmeeda,et al. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors , 2006, Molecular Cancer Therapeutics.
[8] D. Matei,et al. Pegylated liposomal doxorubicin in ovarian cancer , 2009, Therapeutics and clinical risk management.
[9] D. Newton,et al. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. , 2001, Blood.
[10] Jay K. Nathan,et al. High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells1 , 2006, The Journal of Immunology.
[11] Jason E Gestwicki,et al. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. , 2002, Journal of the American Chemical Society.
[12] W. Wilson,et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.
[13] Paul Debbage,et al. Targeted drugs and nanomedicine: present and future. , 2009, Current pharmaceutical design.
[14] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[15] Ken Donaldson,et al. Resolving the nanoparticles paradox. , 2006, Nanomedicine.
[16] I. Pastan,et al. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. , 2008, Cancer research.
[17] K. Haas,et al. CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo1 , 2006, The Journal of Immunology.
[18] C. Bertozzi,et al. Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands. , 2001, Biochemistry.
[19] H. Nakanishi,et al. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. , 2008, Cancer letters.
[20] J. Uhr,et al. Disseminated or localized growth of a human B‐cell tumor (Daudi) in scid mice , 1990, International journal of cancer.
[21] Rajesh Singh,et al. Nanoparticle-based targeted drug delivery. , 2009, Experimental and molecular pathology.
[22] B. Hancock,et al. Non-Hodgkin lymphoma , 2003, The Lancet.
[23] H. Pralle,et al. [Hairy cell leukemia]. , 1976, Hamatologie und Bluttransfusion.
[24] Takeshi Kobayashi,et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. , 2006, Cancer research.
[25] D. Jackson,et al. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. , 2001, Blood.
[26] James C Paulson,et al. Cell surface biology mediated by low affinity multivalent protein-glycan interactions. , 2004, Current opinion in chemical biology.
[27] N. Rooijen,et al. In vivo" depletion of macrophages by liposome-mediated "suicide". , 2003 .
[28] I. Pastan,et al. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] J. Paulson,et al. Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells. , 2008, Journal of the American Chemical Society.
[30] J. Paulson,et al. Sialoside analogue arrays for rapid identification of high affinity siglec ligands. , 2008, Journal of the American Chemical Society.
[31] S. Giannouli,et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. , 2002, Anticancer research.
[32] L. Pulliam,et al. Sialoadhesin Expressed on IFN-Induced Monocytes Binds HIV-1 and Enhances Infectivity , 2008, PloS one.
[33] K.,et al. Eradication of Minimal Disease in Severe Combined Immunodeficient Mice With Disseminated Daudi Lymphoma Using Chemotherapy and an Immunotoxin Cocktail , 2000 .
[34] Ajit Varki,et al. Siglecs and their roles in the immune system , 2007, Nature Reviews Immunology.
[35] P. Quesenberry,et al. Newer monoclonal antibodies for hematological malignancies. , 2008, Experimental hematology.
[36] Y. Tano,et al. High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. , 2008, Experimental eye research.
[37] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[38] E. Jones,et al. Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. , 2003, Structure.
[39] A. Saven,et al. Hairy cell leukemia. , 2008, Cancer treatment and research.
[40] E. Sotomayor,et al. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. , 2007, Hematology. American Society of Hematology. Education Program.
[41] T. Allen,et al. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[42] P. Crocker,et al. Sialoadhesin-Deficient Mice Exhibit Subtle Changes in B- and T-Cell Populations and Reduced Immunoglobulin M Levels , 2006, Molecular and Cellular Biology.
[43] A. Saven,et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. , 1993, Blood.
[44] Chien-Hsun Wu,et al. A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human Lung Cancer , 2009, PloS one.
[45] B. Nathwani,et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] N. Damle,et al. Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma , 2006, Clinical Cancer Research.
[47] Kenneth G. C. Smith,et al. CD22: an inhibitory enigma , 2008, Immunology.
[48] A. Molina. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. , 2008, Annual review of medicine.
[49] James C Paulson,et al. Siglecs as targets for therapy in immune-cell-mediated disease. , 2009, Trends in pharmacological sciences.